Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a research report report published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $6.00 price target on the stock.

A number of other research firms also recently issued reports on CTXR. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, December 1st. Wall Street Zen downgraded shares of Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, September 26th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Citius Pharmaceuticals Stock Performance

CTXR stock opened at $1.18 on Thursday. The company’s 50-day simple moving average is $1.33 and its 200 day simple moving average is $1.29. Citius Pharmaceuticals has a 52 week low of $0.65 and a 52 week high of $5.95. The company has a market capitalization of $20.07 million, a PE ratio of -0.35 and a beta of 1.51.

Institutional Trading of Citius Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Arkadios Wealth Advisors raised its position in Citius Pharmaceuticals by 100.0% during the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock valued at $32,000 after purchasing an additional 10,000 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter valued at $32,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Citius Pharmaceuticals during the 2nd quarter worth $40,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.